, and 54.8% of children were classified as having WHO stage 3 or 4 disease. In total, 18 transient CD4 <200 events, 2 confirmed CD4 <200 events, and10 clinical failures occurred at rates of 0.73 (95% confidence interval [95% CI], 0.46-1.16), 0.08 (95% CI, 0.02-0.32), and 0.40 (95% CI, 0.22-0.75) events per 100 patient-years, respectively. CD4 <500 cells/mm 3 at the time of viral suppression confirmation was associated with higher rates of both CD4 outcomes.
Conclusions Regular CD4 testing may be unnecessary for virally suppressed children aged 5-15 years with CD4 ≥500 cells/ mm 3 . Keywords. CD4 cell count monitoring; pediatrics; viral suppression.
Human immunodeficiency virus (HIV) viral load monitoring accurately detects treatment failure before CD4 cell count decline or clinical deterioration, thereby providing an early indication of the need to enhance adherence support or switch antiretroviral therapy (ART) [1] . The World Health Organization (WHO) recommends regular viral load testing as the preferred method of monitoring ART [2] , and substantial efforts are being made to support the scale-up of viral load capacity in resource-limited areas. An important aspect of this scale-up involves redirecting resources that could be used more efficiently.
CD4 count is a strong predictor of disease progression and mortality in people with HIV [3] [4] [5] [6] [7] [8] [9] [10] . It is also an important tool for assessing ART eligibility and the need to initiate opportunistic infection prophylaxis [2] . Regular CD4 count testing can be used to monitor ART efficacy; however, this role is increasingly considered unnecessary in patients who are known to be virally suppressed [11] [12] [13] [14] [15] [16] [17] .
In 2014, the WHO released a policy brief which stated that CD4 monitoring could be stopped in virally suppressed patients for whom routine viral monitoring is available [18] . However, there are limited data supporting this recommendation in children, and it remains unclear whether this guidance applies to those with a low CD4 cell count on ART. A recent report from South Africa found that there was a 2.8% probability of severe immunosuppression over 3 years of follow-up in HIV-positive children aged ≥2 years who, at the time of viral suppression, had minimal immunosuppression and had been on ART for <18 months [17] . Pediatric data from Asia are currently lacking. We addressed this issue by analyzing the TREAT Asia Pediatric HIV Observational Database (TApHOD).
METHODS

Study Population
The TApHOD data collection is based on a standardized set of demographic, monitoring, and treatment variables that have been described previously [19] . Recruitment started in 2008 and involves 16 pediatric centers in Cambodia (n = 1), India (n = 1), Indonesia (n = 2), Malaysia (n = 4), Thailand (n = 5), and Vietnam (n = 3). These sites are predominantly public or university-based pediatric HIV referral clinics. Ethics approval has been obtained at the sites, the coordinating center (TREAT Asia/amfAR), and the data management and statistical analysis center (The Kirby Institute, University of New South Wales Australia). Patient consent is deferred to the individual participating sites and their institutional review boards.
Children were eligible for inclusion in this analysis if they (1) were receiving ≥3 antiretroviral agents for ≥6 months, (2) had confirmed viral suppression, defined as 2 consecutive viral load measurements <400 copies/mL and a CD4 count ≥200 cells/ mm 3 , all within a 390-day period, (3) were aged 5-15 years at the time of confirmed viral suppression, (4) had a minimum of 1 subsequent viral load measurement <400 copies/mL at least 12 months after confirmed viral suppression, and (5) had a minimum of 1 CD4 measurement 6 months after confirmed viral suppression. Follow-up time was only counted while virally suppressed patients had CD4 count monitoring every 6 months. A break in regular CD4 count testing resulted in censoring. A 3-month window on either side of the 6-monthly CD4 cell count date was used. Patients may have had more than 1 CD4 count measurement within this period, but the measurement closest to the 6-month date was considered the primary measurement. All subsequent CD4 measurements were evaluated when determining the CD4 outcomes described below.
Outcomes and Collected Data
Study end points were as follows: (1) a CD4 count <200 cells/mm 3 followed by a CD4 count ≥200 cells/mm 3 (transient CD4 <200); (2) CD4 count <200 cells/mm 3 confirmed within 6 months (confirmed CD4 <200); and (3) a new or recurrent WHO stage 3 or 4 illness (clinical failure). A CD4 count threshold of 200 cells/ mm 3 was used because measurements that drop below this level indicate the need for opportunistic infection prophylaxis in all settings [2] . Subanalysis was also undertaken to evaluate the sensitivity of our findings when 350 cells/mm 3 was used as the CD4 count threshold in children with a CD4 count ≥350 cells/mm 3 at baseline. The subanalysis end points were as follows: (1) a CD4 count <350 cells/mm 3 followed by a CD4 count ≥350 cells/mm 3 (transient CD4 <350); and (2) CD4 count <350 cells/mm 3 confirmed within 6 months (confirmed CD4 <350).
Data included age, sex, mode of HIV exposure, orphan status, primary care giver status, history of previous acquired immune deficiency syndrome diagnoses, height, weight, hemoglobin, hepatitis B and C serologies, and ART regimen. Baseline was defined as the date of confirmed viral suppression. Anemia was defined according to the age-and sex-specific limits defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events [20] .
Statistical Analysis
Rates and predictors of transient CD4 <200, confirmed CD4 <200, transient CD4 <350, confirmed CD4<350, and clinical failure were analyzed by Kaplan-Meier curves and Cox regression. Patients could only contribute a single outcome in each analysis. If the last biannual CD4 count was <6 months before an ART class change or a final viral load measurement <400 copies/mL, then follow-up time was censored at the date of ART class change or final suppressed viral load (whichever occurred first). If the last biannual CD4 count occurred >6 months before an ART class change or a final viral load of <400 copies/mL, then follow-up time was censored 6 months after the final biannual CD4 count. Antiretroviral therapy class change was defined as a substitution or cessation of ≥1 antiretroviral drug class in the regimen being used at the beginning of viral suppression. Univariate and multivariate predictors were considered significant if they exhibited a P value ≤.05. Stata statistical software (version 14.1; StataCorp, College Station, Texas) was used for all statistical analysis.
RESULTS
As of September 2014, a total of 5609 children were enrolled in TApHOD. Of these, 1792 had been using ART for ≥6 months and had documentation of confirmed viral suppression between age 5 and 15 years; 967 had a follow-up viral load and at least 6-monthly CD4 monitoring and were therefore eligible for this analysis (see Supplementary Figure 1 ). Baseline characteristics of the study population are shown in Table 1 . The median rate of viral load monitoring while enrolled in TApHOD and using ART was 1.4 (interquartile range, 1.1-2.0) tests/year among eligible children.
Overall, and in children with a baseline CD4 count >750 cells/ mm Figure 1 shows the cumulative probability of transient CD4 <200, confirmed CD4 <200, and clinical failure by baseline CD4 category. After 5 years, the probabilities of transient CD4 <200 in patients with baseline CD4 count 200-499, 500-750, and >750 cells/mm 3 were 7.7%, 3.7%, and 2.1%, respectively (log-rank test 0.07). Confirmed CD4 <200 only occurred in children with a baseline CD4 count between 200 and 499 cells/mm 3 ; the 5-year cumulative probability of confirmed CD4 <200 in this group was 4.3% (log-rank test <0.01). The 5-year probabilities of clinical failure with baseline CD4 count 200-499, 500-750, and >750 cells/mm 3 were 0.7%, 1.1%, and 2.0%, respectively (log-rank test 0.79). Given the low number of events, our regression analyses were limited to investigating transient CD4 <200. The only baseline factor significantly associated with transient CD4 <200 in univariate analysis was CD4 count (hazard ratio [HR] = 1.09 for every 50 cells/mm 3 lower; 95% CI, 1.01-1.18; P = .03). In a subanalysis of patients with a baseline CD4 ≥350 cells/ mm 3 (n = 917), 58 transient CD4 <350 events occurred at a rate of 2.57 (95% CI, 1.99-3.33) per 100 patient-years, and 11 confirmed CD4 <350 events occurred at a rate of 0.47 (95% CI, 0.26-0.84) per 100 patient-years. After 5 years, the probabilities of transient CD4 <350 in patients with baseline CD4 count 350-499, 500-750, and >750 cells/mm 3 were 25.9%, 16.2%, and 7.5%, respectively (log-rank test <0.01). The 5-year probabilities of confirmed CD4 <350 in patients with baseline CD4 count 350-499, 500-750, and >750 cells/mm 3 were 15.8%, 4.4%, and 0.7%, respectively (log-rank test <0.01) (see Supplementary  Figure 2 ). The only baseline factors significantly associated with transient CD4 <350 in univariate analysis were age (HR = 1.16 for every year older; 95% CI, 1.06-1.28; P < .01) and CD4 count (HR = 1.17 for every 50 cells/mm 3 lower; 95% CI, 1.10-1.24; P < .01). In multivariate analysis, baseline age became nonsignificant after adjustment for baseline CD4 cell count.
DISCUSSION
Virally suppressed children in this study generally had stable CD4 count measurements over time, and overall rates of transient CD4 <200, confirmed CD4 <200, confirmed CD4 <350, and clinical failure were less than 1% per year. Median CD4 count remained lowest over 5 years of follow-up in those with a low baseline CD4 count. Accordingly, children with a low baseline CD4 count were at the greatest risk of transient and confirmed CD4 <200 and transient and confirmed CD4 <350. Rates of clinical failure were ≤2% in all baseline CD4 count categories evaluated.
CD4 count tends to increase gradually in virally suppressed adults regardless of baseline CD4 count [11] . In contrast, we found overall median CD4 count declined after baseline, which was driven by children with a baseline CD4 >750 cells/mm 3 . This is most likely explained by the biologic decline in CD4 count observed during childhood [21] [22] [23] . Our results provide reassurance that, even though CD4 count may decline in virally suppressed children with a high baseline CD4 level, the risk of serious immune suppression and subsequent need to consider opportunistic infection prophylaxis remains low. Furthermore, although children with a baseline CD4 count ≥500 cells/mm 3 exhibit a moderate risk of a transient CD4 count <200 cells/ mm 3 and a reasonably high risk of a transient CD4 count <350 cells/mm 3 , there seems to be a low probability that such levels of immune suppression will be sustained while viral load is undetectable. More importantly, the clinical relevance of a single low CD4 count is questionable in HIV-infected patients because it is usually reversed without intervention and often associated with physiological variation, acute illness, or the use of bone marrow-suppressing medication [12, 17, 24] .
Our results add to those of the study by Davies et al [17] on virally suppressed, HIV-infected children living in South Africa. In their study, median age was 5.8 years and the probability of a single CD4 count indicating severe immune suppression was 6.6% over 3 years of follow-up (2.2%/year). The authors also reported that severe immune suppression resolved in 86% of children with a subsequent CD4 count. It is notable that the rate of transient CD4 <200 in our study (0.73%/year) was lower than that of severe immune suppression in the African cohort. This could be because children with a CD4 count <200 cells/mm 3 and no subsequent CD4 count were censored in our analysis. The older age of our study population may also have been an influence, because Davies et al [17] reported that the rate severe immune suppression was lower among children aged ≥2 years at baseline compared with those aged <2 years. Regardless of these results, the overarching message from both studies is that clinically relevant CD4 decline is rare among virally suppressed children. Our study had several limitations. First, our definition of viral suppression was based on 2 consecutive measurements <400 copies/mL. This was to account for the different viral load test thresholds over the history of the TApHOD cohort. However, current testing methods are able to detect virus present at >20 copies/mL, meaning that some patients with a detectable viral load at this threshold may have been included in our analysis. Our rates of CD4 decline and clinical failure might have been even lower if we could have reliably defined a lower cutoff point for viral suppression. In addition, the observational nature of TApHOD data collection limited the assessment of specific events, medications, or interventions that may have been related to the CD4 declines documented.
CONCLUSIONS
Virally suppressed children aged 5-15 years in our Asian cohort with a baseline CD4 cell count ≥500 cells/mm 3 had a low risk of clinically relevant CD4 count decline or clinical failure. Reducing or discontinuing regular CD4 count monitoring in this population may be a safe intervention that would help pediatric HIV programs with viral load capacity to utilize their resources more effectively. This could also enhance the feasibility of expanding routine viral load monitoring across the region. Future work should seek to establish the safety of reduced CD4 count monitoring in children <5 years of age and in children with a baseline CD4 measurement <500 cells/mm 3 .
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